

WILLIAM A. WELLS

268 E Broadway #A1402, New York, NY 10002 USA

Phone: +1-917-974-9855

E-mail: william.a.wells@gmail.com

EDUCATION

Columbia University, School of International and Public Affairs

Master of International Affairs (2004-2006).

Concentrations in Economic and Political Development and Public Health.

University of California, San Francisco

Ph.D. in Cell Biology (1990-1995). Offered Fulbright scholarship.

University of Adelaide, South Australia, Bachelor of Science with Honors (1986-1989).

PUBLIC HEALTH EXPERIENCE

Senior TB Technical Advisor (2013-2025)

United States Agency for International Development, Washington, DC (USAID)

- Provided strategic and technical guidance globally and to individual countries – including project design and global strategy development – with a special focus on health systems strengthening, health financing, private provider engagement, and operations research.
- Established a workstream on TB and financing at USAID, including guiding strategic purchasing for TB in Indonesia, establishing (Bangladesh) or optimizing (India) contracting of TB and other health services, and designing and implementing a framework for sustainable TB financing in 12 countries.
- Oversaw a TB portfolio of ~\$45m; guided USAID projects in countries including Bangladesh, Cambodia, Ethiopia, India, Indonesia, Kenya, Myanmar, Nigeria, South Africa and the Philippines.
- Structured USAID's approach to annual TB planning across 23 USAID country missions.
- Provided detailed technical guidance in Asia and Africa on: diagnostic scale-up planning; electronic data capture; operational research on short regimens; community TB strategies; domestic resource mobilization; TB investment strategies; and private provider engagement strategies.
- Contributed to international guidance on the End TB strategy, social protection, measurement of catastrophic costs for patients, and integration of TB into national health insurance.
- Team leader on national TB program reviews in Bangladesh, Indonesia, Myanmar, Philippines, and South Africa.

Director, Market Access (2008-2013) and Senior Communications Officer (2007-2008)

The Global Alliance for TB Drug Development, New York, NY (www.tballiance.org)

- Identified the health systems context for new TB regimen adoption, and mechanisms to ensure successful adoption, availability, and affordability of new TB drugs.
- Drafted strategy for new Market Access Department.
- Conducted comprehensive market and value analysis for new TB regimens including demand forecasting, cost effectiveness, private sector manufacturing and sales, options for product presentation, patient costs and perceptions, public sector regimen change, and the adoption pathways in the 22 countries with the highest TB burdens; published in peer-reviewed publications.
- Managed budgets, contracting, multi-country implementation, and supervision of consultants.
- Defined the need to integrate new regimens and new diagnostics; proposed clinical algorithms.
- Co-convened first large-scale meeting on access between product development partnerships (PDPs). Co-Chair of PDP Access Group; initiated cooperative project to analyze approaches of different PDPs to pricing, manufacturing, financing, pharmacovigilance, and country decision making.

Consultant, World Health Organization (WHO) (2005-2013)

June 2013, Suva, Fiji, and Port Vila, Vanuatu

Assessed and provided recommendations on the response to STIs in Fiji and Vanuatu – two Pacific Island Countries with >25% chlamydia prevalence among ante-natal clinic clients.

August 2012, Phnom Penh, Cambodia

Evaluated Cambodia's achievement of Universal Access to antiretroviral treatment, and recommended approaches to future strategies, including Treatment as Prevention.

March and July 2012, Manila, Philippines

Assessed models for connecting MSM to HIV testing in the Philippines, as a response to a dramatic expansion of the local HIV epidemic. Report endorsed to Minister of Health.

December 2011 and April 2012, Vientiane, Lao PDR

After Global Fund R11 cancellation, assessed funding and program options for national HIV response. Worked with 5 NGO and 5 government subrecipients to draft a Global Fund renewal.

September 2011, Phnom Penh, Cambodia

Evaluated the Cambodia HIV program's Continuous Quality Improvement initiative.

August 2011, Port Moresby, Papua New Guinea

Outlined options for continued involvement of the National Department of Health in Global Fund grant implementation after transfer of Principal Recipient role to other organizations.

May 2011, Phnom Penh, Cambodia

Reviewed existing monitoring and evaluation of Cambodia's TB/HIV program; designed a standard operating protocol to strengthen data capture and quality.

Mar-April 2011, Vientiane and Luang Prabang, Lao PDR

Reviewed linkage opportunities between HIV, malaria, TB, MNCH and EPI programs in Lao PDR, with a focus on district-level activities.

October 2010, Phnom Penh and provincial sites, Cambodia

Evaluated and documented Cambodia's progress in implementing joint TB/HIV activities.

June-July 2010, Port Moresby, Papua New Guinea

Lead writer and coordinator of successful \$46 million Round 10 HIV application to the Global Fund, working with Papua New Guinea's CCM, national program and 10 NGO subrecipients.

Jan-Feb 2010, Port Moresby, Papua New Guinea

Coordinated development of a successful Continuity of Services (CoS) application to the Global Fund.

December 2008, Manila, Philippines

Evaluated WHO's regional involvement with Global Fund, resulting in published policy document.

May-June 2007, Manila, Philippines, and Guilin, China

Drafted Asia-Pacific Operational Framework for Linking STI/HIV Services with Reproductive, Maternal and Child Health. Moderated regional consultation and generated final guidance.

Nov 2005-Feb 2006, New York, USA, and Phnom Penh and provincial sites, Cambodia

Assessed the positive and negative spillover effects of HIV programs (specifically, the Continuum of Care (CoC)) on the rest of the healthcare system in Cambodia.

United Nations Children's Fund (UNICEF), Cambodia

Mar-May 2007; Consultancy, Phnom Penh, Cambodia

Coordinated development of the orphans and vulnerable children (OVC) subcomponent of Cambodia's application for Round 7 of the Global Fund.

Foundation for AIDS Research (amfAR)

April-June 2006; Consultancy, New York, USA

Wrote 30-page advocacy paper explaining need for MSM prevention programs in Asia. CD copies were distributed to all registrants at the 2006 Toronto AIDS meeting.

Mar-Aug 2005; Consultancy, New York, USA and Kobe, Japan

Wrote successful grant application for the International Epidemiologic Database to Evaluate AIDS, including a 35 page research plan and multi-million dollar budget.

United Nations Population Fund (UNFPA), Sudan

Oct 2005-Apr 2006; Group Consultancy, New York, USA, and Khartoum, Sudan

Population and Reproductive Health Assessment for UN country team.

EDITORIAL EXPERIENCE

News Director (2006-2007), Senior News Editor (2004-2006) and News Editor (2001-2004)

Rockefeller University Press, New York, NY (www.rockefeller.edu/rupress; www.jcb.org; www.jem.org)

- Created news sections in two major scientific journals, then wrote, commissioned and edited for these news sections. This involved hiring and directly supervising three staff writers, multiple freelance writers, and two designers, and coordinating production with ~20 additional editorial staff.
- Directed redesigns of both journals and oversaw public policy for a University Press. Invited to speak on science policy at Harvard Medical School and other locations, and to teach science writing courses at University of Pennsylvania, Harvard Medical School, Rockefeller University, and Beijing University (course later modified for CARE, WHO and FHI in Cambodia).

Freelance Scientific Writer and Editor (1996-2001)

- Wrote hundreds of feature and news articles for publications including *New Scientist* and *Forbes*.
- Wrote educational materials (distributed nationally) for schools and US congress.
- Sole staff writer for major US National Academy of Sciences report on "Scientific and Medical Aspects of Human Reproductive Cloning".

In-house Editor (1995-1996)

Current Biology Ltd., San Francisco, CA.

Reached editorial decisions on accepting research manuscripts.

PEER-REVIEWED PUBLICATIONS

Peer-reviewed publications in global public health include the following:

Wells WA,* Waseem S, Scheening S. The intersection of TB and health financing: defining needs and opportunities. *IJTLD Open*. 2024 Sep 1;1(9):375-383.

Muniyandi M, Ramesh PM, **Wells WA**, Alavadi U, Sahu S, Padmapriyadarsini C. The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB. *Trop Med Infect Dis*. 2023. 8(8):411.

Klinton JS, Heitkamp P, Rashid A, Faleye BO, Win Htat H, Hussain H, Syed I, Farough K, Mortera L, Moh Lwin M, Jha N, Ananthakrishnan R, Mahfuza R, Chadha SS, Banu S, Mannan S, Vijayan S, Ahmed S, Ali T, Oga-Omenka C, Kaur M, Singh U, **Wells WA**, Stallworthy G, Dias HMY, Pai M. One year of COVID-19 and its impact on private provider engagement for TB: A rapid assessment of intermediary NGOs in seven high TB burden countries. *J Clin Tuberc*. 2021. 100277.

Piatek AS, **Wells WA,*** Shen KC, Colvin CE. Realizing the "40 by 2022" Commitment from the United Nations High-Level Meeting on the Fight to End Tuberculosis: What Will It Take to Meet Rapid Diagnostic Testing Needs? *Glob Health Sci Pract*. 2019. 7:551-563.

Schumacher SG, **Wells WA**, Nicol MP, Steingart KR, Theron G, Dorman SE, Pai M, Churchyard G, Scott L, Stevens W, Nabeta P, Alland D, Weyer K, Denkinger CM, Gilpin C. Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. *J Infect Dis*. 2019. 220(Suppl 3):S99-S107.

Denkinger CM, Schumacher SG, Gilpin C, Korobitsyn A, **Wells WA**, Pai M, Leeflang M, Steingart KR, Bulterys M, Schünemann H, Glaziou P, Weyer K. Guidance for the Evaluation of Tuberculosis

- Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles. *J Infect Dis*. 2019. 220(Suppl 3):S91-S98.
- Wells WA**.* Avoiding false economies: paying for community tuberculosis outcomes. *Public Health Action*. 2019. 9:49.
- Wells WA**.* Scale and Ambition in the Engagement of Private Providers for Tuberculosis Care and Prevention. *Glob Health Sci Pract*. 2019. 7:3-5.
- Wells WA**.* Stallworthy G, Balsara Z. How tuberculosis programs can navigate the world of social health insurance. *Int J Tuberc Lung Dis*. 2019. 23:26-37.
- Wells WA**.* Stallworthy G. Meet the patients where they are: A greater ambition for private provider engagement for TB. *J Clin Tuberc Other Mycobact Dis*. 2019. 14:14-15.
- Wells WA**.* Onions and prevalence surveys: how to analyze and quantify tuberculosis case-finding gaps. *Int J Tuberc Lung Dis*. 2017. 21:1101-1113.
- Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, **Wells WA**, Cobelens FG, Vassall A. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. *BMC Infect Dis*. 2016. 16:726.
- Uplekar M, Atre S, **Wells WA**, Weil D, Lopez R, Migliori GB, Raviglione M. Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice. *Eur Respir J*. 2016. 48:1571-1581.
- Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, **Wells WA**, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. Population-based resistance of *Mycobacterium tuberculosis* isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. *Lancet Infect Dis*. 2016. 16:1185-92.
- Trajman A, Bastos ML, Belo M, Calaça J, Gaspar J, dos Santos AM, dos Santos CM, Brito RT, **Wells WA**, Cobelens FG, Vassall A, Gomez GB. Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services. *BMC Health Services Research*. 2016. 16:27. doi:10.1186/s12913-016-1269-x.
- Knight GM, Gomez GB, Dodd P, Dowdy D, Zwerling A, **Wells WA**, Cobelens F, Vassall A, White RW. The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa. *PLoS ONE*. 2015. 10(12): e0145796.
- Wells WA**.* Uplekar M, Pai M. Achieving systemic and scalable private sector engagement in TB care and prevention in Asia. *PLOS Med*. 2015. 12(6): e1001842. doi:10.1371/journal.pmed.1001842.
- Denkinger CM, Dolinger D, Schito M, **Wells WA**, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. *J Infect Dis*. 2015. 211(suppl 2):S29-S38.
- Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, Rahman M, Hussain MA, Haque MN, Egwaga S, Gardiner E, PrayGod G, Islam MA, Mann GH, **Wells WA**, Squire SB. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. *Int J Tuberc Lung Dis*. 2014. 18:810-7.
- Wells WA**, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. *Lancet Infect Dis*. 2013. 13:449-58.
- Eang MT, Vun MC, Eam KK, Sovannarith S, Sopheap S, Bora N, Yadav R, Fujita M, Tomas B, Ghidinelli M, van Maaren P, **Wells WA**.* The multi-step process of building TB/HIV collaboration in Cambodia. *Health Res Policy Syst*. 2012. 10:34.
- Wells WA**.* Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. *PLoS ONE*. 2011. 6:e18964. Findings from this study were picked up by the Financial Times, the Telegraph (Calcutta), the Times of India, *Nature Medicine*, Aidsmap, and Radio Australia.

Wells WA,* Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR. Implications of the current tuberculosis treatment landscape for future regimen change. *Int J Tuberc Lung Dis.* 2011. 15:746-53.

Wells WA,* Brooks A. Adoption of new health products in low and middle income settings: How product development partnerships can support country decision making. *Health Res Policy Syst.* 2011. 9:15.

Wells WA,* Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR. Tuberculosis regimen change in high-burden countries. *Int J Tuberc Lung Dis.* 2010. 14:1538-47.

Brooks AD, **Wells WA,** McLean TD, Khanna R, Coghlan R, Mertenskoetter T, Privor-Dumm LA, Krattiger A, Mahoney RT. Ensuring that developing countries have access to new healthcare products: The role of product development partnerships. *Innov Strat Today.* 2010. 3:1-5.

Schwalbe NR, **Wells WA,*** Geaneotes AP, Forcellina A, Lee MG, Dicola L, Ignatius HR, Walker CL, Raafat T, Patel N. Estimating the market for tuberculosis drugs in industrialized and developing nations. *Int J Tuberc Lung Dis.* 2008. 12:1173-81.

*Corresponding author.